Cerebral energy metabolism in Alzheimer disease (AD) has recently been given increasing attention. This study focuses on the alterations of cerebral lactate metabolism in the double-transgenic amyloid precursor protein/presenilin 1 (APP/PS1) mouse model of AD. Immunofluorescence staining and Western blotting analysis were used to identify the alterations of lactate content and lactate transporters (MCT1, MCT2, MCT4) in APP/PS1 mouse brains, which display amyloid beta plaques, reduced amounts of neurons and oligodendrocytes, and increased quantity of astrocytes. We found that lactate content and expressions of cerebral MCT1, MCT2, and MCT4 were decreased in APP/PS1 mice. In particular, lactate dehydrogenase A (LDHA) and B (LDHB) were reduced in neurons with increased ratios of LDHA and LDHB. This study suggests that the decreases of cerebral lactate content and lactate transporters may lead to the blockage of lactate transport from glia to neurons, resulting in neuronal lactate deficit. The increased ratio of neuronal LDHA and LDHB may represent a reaction of neurons to lactate deficit, although it cannot reverse the energy deficiency in neurons.
INTRODUCTION
Alzheimer disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and dementia and has a prevalence of $3% at age 65 and 55% at age 95 (1, 2) . Tau-containing neurofibrillary tangles (NFTs) and cerebral accumulation of amyloid beta (Ab) peptide are the molecular hallmarks of AD (3, 4) . Tau protein undergoes posttranslational modification. In particular, phosphorylation can alter the conformation and regulate the biological activity of tau protein, which result in the aggregation of tau protein and formation of NFTs (5) . On the other hand, the formation of Ab plaques is associated with inflammation, oxidative stress, mitochondrial dysfunction, and energy deficit (5, 6) . In particular, alterations in cerebral glucose metabolism, including glycolysis and oxidative metabolism, have been identified in individuals of familial AD before the manifestation of Ab plaques (6, 7) . The suppression of cerebral glucose utilization is associated with cognitive dysfunction in AD (8) , and altered cerebral energy metabolism contributes to AD development (6) (7) (8) . The glutamate-glutamine cycle is involved in cellular metabolism of neurons and glial cells. The glutamate produced in this cycle can be converted into a-ketoglutarate, a substrate of the tricarboxylic acid (TCA) cycle (9) . In double-transgenic amyloid precursor protein/presenilin 1 (APP/PS1) mice, (a model of AD), reduction in glutamine uptake and suppression in oxidative glutamine metabolism can impair homeostasis of the glutamate-glutamine cycle and inhibit neurotransmission and TCA cycle activity (10) (11) (12) . This suggests that brains in AD patients may remain in a cerebral hypometabolic state.
Twenty-five percent of total body glucose is utilized to transduce energy through glycolysis and mitochondrial oxidative phosphorylation in the brain (13) . As the main energy substrate of neurons and glial cells, glucose can be derived through 2 processes: Transport across the blood-brain barrier and intracellular catabolism (14) . In aging and AD brains, glucose metabolism is hampered because of a decline in neuronal glucose uptake, decrease in electron transport chain activity, mitochondrial dysfunction and increase in oxidant production (8, 15) . The glycolytic pathway represents an adaptive mechanism that permits sufficient energy production and defends against Ab-mediated impairment of mitochondrial respiration (16, 17) . Specifically, nerve cells selected for resistance against Ab toxicity exhibit a shift in metabolism from preferring mitochondrial oxidation to favoring the glycolytic pathway (18, 19) . Nevertheless, cerebral lactate content is still decreased in the Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -treated rat model of AD compared with control (20) . Thus, it is assumed that the enhancement of glycolytic pathway and increased lactate production may be a protective reaction of the brain to Ab toxicity. However, alterations of lactate and its metabolism in AD brains have not been fully analyzed.
In the central nervous system (CNS), lactate trafficking among neural cells is facilitated by monocarboxylate transporter 1 (MCT1), monocarboxylate transporter 2 (MCT2), and monocarboxylate transporter 4 (MCT4), which belong to the monocarboxylate transporter (MCT) family (21) . MCT1 is predominantly expressed in endothelial cells and is exclusively expressed in oligodendrocytes (OLs) and myelin (22) (23) (24) . MCT2 is considered to be the main neuronal transporter (25, 26) , and MCT4 is particularly localized to astrocytes (27) (28) (29) . This cellular distribution of MCT1, MCT2, and MCT4 in the CNS may signify their subcellular specificity in lactate transport (28) . Indeed, MCT1 mainly functions in the release of lactate from OLs or myelin (21, 22) ; MCT4 predominantly facilitates lactate outflux from astrocytes (30) ; and MCT2 mainly facilitates lactate uptake into neurons (25, 31) . Previous studies have shown that MCT1, MCT2, and MCT4 play vital roles in lactate transport, which is required for memory formation and synaptic transmission in the hippocampus (32) (33) (34) . On the other hand, dysfunction of MCT1, MCT2, and MCT4 may lead to the incapability of lactate transport, further hampering energy metabolism and inducing memory deficit. Moreover, it was found that MCT2 and lactate levels were decreased in cerebral cortex and hippocampus in an Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -treated rat model of AD (20) . At the cellular level, lactate dehydrogenase A (LDHA) is involved in lactate production, and lactate dehydrogenase B (LDHB) catalyzes lactate into pyruvate in a metabolic pathway (16) . The increased ratio of intracellular LDHA/LDHB can benefit cellular lactate accumulation (16) . In particular, the increased lactate level in neurons is beneficial to neuronal activity (25) . However, alterations in lactate content and expressions of cerebral lactate transporters LDHA and LDHB in AD brains are not well understood.
This study aimed to investigate the possible changes in cerebral lactate content and expression of cerebral lactate transporters LDHA and LDHB. Furthermore, we explored the possible relationship between neuronal survival and the alterations of lactate metabolism in AD brains. On the basis of these investigations, we propose that the improvement of lactate supplement in neurons can benefit neuronal survival in AD. 
MATERIALS AND METHODS

Animals
Three-month-old heterozygous APP/PS1 mice (n ¼ 8) and their nontransgenic littermates (wild type, n ¼ 8) were used in this study. Animals were housed in individual cages in a controlled environment (temperature, 22 6 1 C; humidity, 50% 6 10%; 12-hour light/12-hour dark cycle). Food and water were available ad libitum. All procedures were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1996). All animal experiments were carried out in accordance with "Army Medical University Committee on the Care and Use of Laboratory Animals".
Reagents
Radio-immunoprecipitation assay (RIPA) lysis buffer (Beyotime, Shanghai, China) and phenylmethyl sulfonylfluoride ([PMSF] Beyotime) were used to prepare homogenates of brain tissues. The BCA protein assay kit (Beyotime) was used to determine protein concentrations. Lactate levels were detected using a lactate assay kit (Nanjing Jiancheng, Jiangsu, China). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis In addition, horseradish peroxidase conjugated secondary antimouse antibody (Zhongshan) was used in Western blot.
Tissue Processing
Following perfusion with phosphate buffer solution (PBS), pH 7.4, the left hemispheres of brains from APP/PS1 mice and wild type mice (n ¼ 4, respectively) were collected and stored in -20 C for lactate measurement. Meanwhile, the right hemispheres of brains were homogenized by RIPA lysis buffer containing 1 mM PMSF. Homogenates were then centrifuged for 20 minutes at 14 000 rpm and concentrations of the supernatants were assayed using the BCA protein assay kit and adjusted to 1.5 mg/mL. Finally, the samples were stored at -20 C for Western blot analysis. For immunohistochemical assays, APP/PS1 mice and wild type mice (n ¼ 4, respectively) under anesthesia were perfused with saline followed by 4% paraformaldehyde (PFA) in PBS and the brains were extracted and postfixed with fresh 4% PFA at 4 C. Tissues were transferred to 30% sucrose solution for 2-3 days and subsequently cut into 20-lm slices.
Measurement of Lactate Concentration
Determinations of lactate concentration were performed with a lactate assay kit. The cortex and hippocampus were homogenized in saline at 4 C for 10 minutes, then the homogenates were centrifuged for 15 minutes at a speed of 2500 rpm. Assay buffers were added to the supernatants and incubated for 10 minutes at 37 C. Finally, optical density (OD) values were recorded at 530 nm after the reaction of lactate and assay buffers. Lactate content was calculated using the following formula:
Lactate content ðmmol=gÞ ¼ ðOD measured value -OD blank value Þ= ðOD standard value -OD blank value Þ Â standard substance content ð3 mmol=LÞ= protein content ðg=LÞ:
Western Blotting
Protein samples were subjected to SDS-PAGE and transferred to PVDF filter membranes. The membranes were blocked with 5% nonfat milk for 1 hour at 37 C and incubated with primary antibodies for 12 hours at 4 C, including mouse anti-Ab, rabbit antiMCT1, rabbit antiMCT2, and rabbit antiMCT4. After washing with TBST, the membranes were incubated for secondary antibodies for 1 hour at 37 C and detected using ECL kit. Finally, the blots were qualified by Image J software (NIH, Bethesda, MD).
Immunofluorescence Staining
Brain sections were probed with mouse anti-Ab and mouse antiNeuN primary antibodies, respectively. Brain sections were incubated overnight with primary antibodies in a humidified chamber at 4 C. Sections were then washed 3 times with PBS for 5 minutes each, followed by incubation with antimouse FITC secondary antibody. For doublelabeling immunofluorescence, sections were incubated with the mixture of 2 primary antibodies overnight at 4 C as follows: Mouse antiMBP and rabbit antiMCT1, mouse antiNeuN and rabbit antiMCT2, mouse antiGFAP and rabbit antiMCT4, mouse antiNeuN and rabbit antiLDHA, and mouse antiNeuN and rabbit antiLDHB, respectively. Fluorescent secondary antibodies, raised in different species (FITC with green signal against mouse and TRITC with red signal against rabbit) were used to locate complexes of antigen/primary antibody. Nuclei were counterstained with DAPI for 5 minutes. Images were obtained using a fluorescence microscope (Olympus, Tokyo, Japan) at 200Â magnifications. Positive expressions of staining pictures were analyzed by integrated optical density (IOD). The IOD values were calculated using Image-Pro Plus 6.0 (IPP6.0) software according to manufacturer's instructions. 
Statistical Analysis
All data are expressed as mean 6 standard deviation (SD). All statistical analyses were performed by Statistical Product and Service Solution (SPSS, IBM version 21) and Prism 6 (GraphPad Prism Software Inc., La Jolla, CA). Results of Western blot and immunofluorescence were analyzed using one-way analysis of variance (ANOVA) and, when needed, by the least significant difference (LSD) test. Differences with p < 0.05 and p < 0.01 were considered statistically significant.
RESULTS
Ab Plaques Are Deposited in the Brains of APP/ PS1 Mice
Ab plaques were spread throughout the brains of APP/ PS1 mice whereas it was hard to find Ab plaques in the brains of wild type mice (Fig. 1A, B) . The number of Ab plaques in the cortex of APP/PS1 mice was more than that of wild type mice (96.5 6 17.8 vs 1.5 6 1.3) (n ¼ 4; p < 0.01). In the CA1 area there was an increase of Ab plaques in APP/PS1 mice in comparison with wild type mice (111.8 6 20.7 vs 1.4 6 1.1) (n ¼ 4; p < 0.01; Fig. 1C ). In addition, cerebral Ab levels were evaluated by Western blot. In APP/PS1 mice, relative expression of Ab was 0.351 6 0.129, which was higher than that of wild type mice (0.015 6 0.009) (n ¼ 4; p < 0.01; Fig. 1D ).
Neurons and OLs Were Reduced and Astrocytes Were Increased in APP/PS1 Mice
NeuN-positive cells spread throughout the brains of APP/ PS1 mice and wild type mice ( Fig. 2A) . NeuN immunoreactivity in APP/PS1 mice was much lower than that of wild type mice. In the cortex, IOD value of NeuN in APP/PS1 mice was 495 000.0 6 136 259.6, which was lower than that of wild type mice (1 089 250.0 6 87 952.2) (n ¼ 4; p < 0.05; Fig. 2B ). Also, NeuN immunoreactivity in APP/PS1 mice in the CA1 area was lower than that of wild type mice (420 000.0 6 82 865.4 vs 712 500.0 6 63 442.9) (n ¼ 4; p < 0.05; Fig. 2B ). The quantities of OLs and astrocytes were evaluated by myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) staining (Fig. 3A) . MBP immunoreactivity of APP/PS1 mice in the 
Cerebral Lactate and Relative Levels of Monocarboxylate Transporter 1, 2, and 4 Were Reduced in APP/PS1 Mice
Cerebral lactate level in APP/PS1 mice was 7.63 6 1.49 mmol/g, lower than that of wild type mice (11.50 6 2.65 mmol/g) (n ¼ 4; p < 0.05; Fig. 4A ). Western blot analysis showed that relative levels of MCT1, MCT2, and MCT4 in the brains of APP/PS1 mice were less than those of wild type mice (Fig. 4B) . Relative expression of MCT1 in APP/PS1 mice was 0.118 6 0. 056, much lower than that of wild type mice (1.142 6 0.216) (n ¼ 4; p < 0.01; Fig. 4C ).
Similarly, the relative level of MCT2 in APP/PS1 mice was lower than that of wild type mice (0.498 6 0.081 vs 1.052 6 0.129) (n ¼ 4; p < 0.05; Fig. 4D ). MCT4 expression in APP/PS1 mice was 0.205 6 0.068, lower than that of wild type mice (0.451 6 0.125) (n ¼ 4; p < 0.05; Fig. 4E ).
MCT1 Expression Was Reduced in the Cortex and CA1 Areas of APP/PS1 Mice
MCT1-positive cells (red) were highly colocalized with MBP (green) in the cortex and CA1 areas (Fig. 5A, C) . Moreover, in the cortex, the IOD value of MCT1 in APP/PS1 mice was 592 500.0 6 136 961.1, lower than that of wild type mice (1 227 500.0 6 172 312.7) (n ¼ 4; p < 0.05; Fig. 5B ). In CA1, the number of MCT1-positive cells in APP/PS1 mice was less than that of wild type. IOD values of APP/PS1 mice and wild type mice were 431 255.0 6 54 772.3 vs 992 501.0 6 177 646.7 (n ¼ 4; p < 0.05; Fig. 5D ).
Immunoreactivity of MCT2 Was Downregulated in the Cortex and CA1 Areas of APP/PS1 Mice
MCT2-positive cells were highly colocalized with neurons in the cortex and CA1 areas (Fig. 6A, C) . There was less MCT2 
MCT4 Expression in Cortex and CA1 Was Reduced in APP/PS1 Mice
MCT4 highly localizes to astrocytes labeled (by GFAP) in the cortex and CA1 regions (Fig. 7A, C) . The IOD value of MCT4 in the cortex of APP/PS1 mice was 110 921.2 6 18 257.4, lower than that of wild type mice (203 755.2 6 20 564.9) (n ¼ 4; p < 0.05). In CA1, the IOD value of MCT4 in APP/PS1 mice was lower than that of wild type mice (46 219.1 6 45 46.2 vs 77 253.6 6 9844.6) (n ¼ 4; p < 0.05).
LDHA in Neurons Was Decreased in APP/PS1 Mice
Double staining for LDHA and NeuN was used to recognize differences of neuronal LDHA expression between APP/PS1 mice and wild type mice. Coexpressed regions of LDHA and NeuN were considered to be the positive expression of neuronal LDHA. In comparison with wild type mice there was a reduction of neuronal LDHA expression in the cortex and CA1 regions of APP/PS1 mice (Fig. 8A,  C) . In the cortex, the IOD value of neuronal LDHA in APP/PS1 mice was 464 521.3 6 52 798.4, lower than that of wild type mice (862 252.5 6 48 815.1) (n ¼ 4; p < 0.05; Fig. 8B ). In CA1, the IOD value of neuronal LDHA in APP/PS1 mice was lower than that of wild type mice (252 513.2 6 29 860.8 vs 431 002.1 6 76 061.4) (n ¼ 4; p < 0.05; Fig. 8D ).
Neuronal LDHB Was Also Reduced in APP/PS1 Mice LDHB expressed in neurons was decreased in the cortex and hippocampus of APP/PS1 in comparison with wild type mice (Fig. 9A, C) . In the cortex, the IOD value of neuronal LDHB in APP/PS1 mice was 332 512.2 6 45 734.7, which was lower than that of wild type mice (1 187 500.0 6 47 871.4) (n ¼ 4; p < 0.05; Fig. 9B ). In the CA1 area, the IOD value of neuronal LDHB in APP/PS1 mice was 105 002.5 6 31 091.3, 
There Was a Striking Decrease of Neuronal LDHB Compared With LDHA in APP/PS1 Mice
To better understand the changes of neuronal LDHA and LDHB, we further analyzed the differences in reduced levels of neuronal LDHA and LDHB in APP/PS1 mice, and the differences in the ratio of neuronal LDHA/LDHB between APP/PS1 mice and wild type mice (Fig. 10A) . In the cortex and CA1 regions of APP/PS1 mice, the weakened expression of neuronal LDHB was more obvious than that of neuronal LDHA. Specifically, in the cortex, the percentage of neuronal LDHB expression in APP/PS1 mice and neuronal LDHB level in wild type mice was less than the percentage of neuronal LDHA expression in APP/PS1 mice and neuronal LDHA level in wild type mice, which was 0.280 6 0.035 vs 0.542 6 0.089 (n ¼ 4; p < 0.05). In the CA1 area, the percentage of neuronal LDHB level in APP/PS1 mice and neuronal LDHB expression in wild type mice was 0.254 6 0.075, which was less than the percentage of neuronal LDHA expression in APP/PS1 mice and neuronal LDHA level in wild type mice (0.600 6 0.086) (n ¼ 4; p < 0.05; Fig. 10B ). There was an increased ratio of neuronal LDHA/LDHB in the cortex and CA1 areas of APP/ PS1 mice versus wild type mice. In the cortex, ratio of neuronal LDHA/LDHB in APP/PS1 mice was 1.423 6 0.285, which was higher than that of wild type mice (0.725 6 0.018) (n ¼ 4; p < 0.05). In the CA1 area, the ratio of neuronal LDHA/LDHB in APP/PS1 mice was higher than that of wild type mice (2.571 6 0.839 vs 1.129 6 0.139) (n ¼ 4; p < 0.05; Fig. 10C ). Experimental data are presented in the Table. DISCUSSION Ab plaques and NFTs in the brain are the pathological hallmarks of AD (35, 36) . Accelerated Ab-accumulation can facilitate early neuronal loss and axonal/presynaptic damage (37) . In AD patients there is a marked neuronal reduction in the hippocampus, a key structure of the medial temporal lobe memory system (38, 39) . Usually, neuronal loss is prominent in the CA1 region, and then spreads throughout the cerebral cortex in AD brains (40) . Accordingly, we assessed Ab plaque burden and neuronal amounts in the cortex and CA1 area. As expected, there was an obvious increase of Ab plaques and neuronal loss in those areas. We found that OLs were reduced and astrocytes were increased in these areas in APP/PS1 mice. 
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A recent positron emission tomography (PET) study found that the spatial distribution of aerobic glycolysis correlated with Ab deposition in individuals with AD. This result indicates a possible link between regional aerobic glycolysis and the later development of AD pathology (41, 42) . In APP/ PS1 mice, glucose uptake is increased in the cortex and the hippocampus in comparison with wild type mice. In particular, an increased glucose uptake is close to the plaques rather than Ab-free cerebral tissues, suggesting that glucose uptake can compensate for Ab deposition (42, 43) . Moreover, it is assumed that the weakened glucose metabolism might be a more accurate marker of neuronal atrophy than Ab accumulation itself because it precedes the onset of clinical symptoms in AD (42, 44) . In the clinic, AD patients display early and progressive reductions of glucose metabolism in cortical and hippocampal regions (45) . Conversely, increased glucose transport into neurons can rescue neuronal toxicity of Ab (45) . Cerebral glucose deficit and hypometabolism indeed exist in AD patients, which can further worsen energy insufficiency and accelerate neurodegeneration under Ab attack.
To meet the calorie demand of the brain, the body may convert to a more efficient way to produce energy rapidly. Some studies have indicated that diet supplementation with ketone bodies can improve mental function in AD patients (46, 47) . However, under physiological conditions, the conversion of anaerobic glycolysis from mitochondrial metabolism is a common mode to adapt the rapid energy deficit in the brain (48) . Related studies showed that lactate levels are increased in cerebrospinal fluid of AD patients accompanying hypometabolized glucose (49) . Despite these data, alterations of glycolytic pathway and lactate metabolism in AD brains are not understood. Here, we assessed lactate levels of cerebral parenchyma and further quantified expressions of lactate transporters, including MCT1, MCT2, and MCT4 in APP/PS1 mice. As the results showed, lactate levels of cerebral parenchyma and lactate transporters were both downregulated in APP/PS1 mice.
CNS lactate is transported among cells with the assistance of MCT1, MCT2 and MCT4 [50] . MCT1 is predominately in OLs and a few specific neuronal populations (51), whereas MCT2 is primarily in neurons and MCT4 in astrocytes (52, 53) . Normally, myelinating OLs release lactate through MCT1, and then the released lactate can be transported into neuronal axons via MCT2 [54] . Astrocytic MCT4 and neuronal MCT2 are necessary for lactate transport from astrocytes to neurons (55) . We found that the expression of MCT1 was reduced along with decreased amounts of OLs. Similarly, MCT2 expression was downregulated in the presence of reduced numbers of neurons. Otherwise, decreased expression of MCT4 correlated with increased quantities of astrocytes. Collectively, these results reveal that expressions of MCT1, MCT2 and MCT4 are decreased in APP/PS1 mice. Furthermore, the amounts of OLs and neurons were reduced, while the numbers of astrocytes were increased. Lactate is produced in neurons by the activity of neuronal lactate dehydrogenase (LDH) (56) . Native LDH consists of 4 LDHA or LDHB subunits assembled in all possible combinations, forming distinct tetrameric LDH isoenzymes (57) . In particular, LDHA isoenzymes favor anaerobic glycolysis, which can catalyze pyruvate into lactate, while LDHB isoenzymes primarily catalyze the conversion of lactate to pyruvate (58, 59) . Interestingly, this study shows that neuronal LDHA and LDHB are reduced, and that decreased levels of neuronal LDHB are more evident than the weakened expression of neuronal LDHA in APP/PS1 mice. Meanwhile, the ratio of neuronal LDHA/LDHB is upregulated in APP/PS1 mice compared with wild type mice. In particular, the increased ratio of neuronal LDHA/LDHB can benefit lactate production in neurons.
On the basis of these data, we propose that reduced expression of MCT1, MCT2 and MCT4 can impede lactate transport from glial cells to neurons. Consequently, neurons become lactate-deficient. Moreover, the reduced cerebral lactate levels further aggravate energy deficiency in neurons. The neurons may upregulate the ratio of neuronal LDHA/LDHB to favor lactate production and partially relieve their lack of energy substrate. However, this compensatory change of enzymes is still insufficient to compensate for calorie deficiency in neurons (Fig. 11) . *Differences with p < 0.05 and **p < 0.01 are considered statistically significant between wild-type mice and APP/PS1 mice.
FIGURE 11. In the brains of APP/PS1 mice, reduced expression of MCT1, MCT2, and MCT4 can aggravate neuronal energy deficit via disturbing lactate transport from glial cells to neurons. Lactate, produced through anaerobic glycolysis, can be transported from astrocytes to neurons through MCT1, MCT2, and MCT4. Additionally, MCT1 and MCT2 can assist lactate transport from oligodendrocytes (OLs) to neurons. Reductions of MCT1, MCT2, and MCT4 impair lactate transport into neurons. Neurons can compensate by autoregulating the relative proportion of intracellular lactate enzymes (LDHA and LDHB) to favor lactate production and resulting in increased LDHA/LDHB ratios. Despite this effect, neurons still cannot reverse their energy deficits.
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